Zacks Investment Research on MSN3d
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
Fierce Biotech3d
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Healthline3d
An Expert Explains Signs It’s Time to Try a Biologic for Eczema
Eczema can be managed with certain self-care ... or mycophenolate mofetil Biologic agents, such as dupilumab (Dupixent) or lebrikizumab-lbkz (Ebglyss), are reserved for people who have tried ...
Eczema: What Does It Look Like & How Can I Treat It?
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Yahoo Finance5d
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...